Skip to main content
. 2015 Sep 29;16(11):1660–1670. doi: 10.1080/15384047.2015.1099769

Figure 1.

Figure 1.

Celecoxib enhances the lethality of [sorafenib + sildenafil] in ovarian cancer cells. (A) OVCAR and SKOV3 cells were treated with vehicle or [sorafenib (2 μM) + sildenafil (2 μM)], and with increasing concentrations of celecoxib (0–4 μM). Twenty four h after drug treatment, cells were processed and subjected to live/dead assays in a Hermes Wiscan system. (B) CAOV-3, CAOV-4 and PA-1 established ovarian tumor cells and MCVH OP1 fresh primary ovarian cancer cells were treated with vehicle or [sorafenib (2 μM) + sildenafil (2 μM) + celecoxib (2 μM)], as indicated in the panel. Twenty four h after drug treatment, cells were processed and subjected to live/dead assays in a Hermes Wiscan system. (C) CRL-1572 established ovarian tumor cells and Spiky primary ovarian cancer cells were treated with vehicle or [sorafenib (2 μM) + sildenafil (2 μM) + celecoxib (2 μM)], as indicated in the panel. Twenty four h and 48h after drug treatment, cells were processed and subjected to live/dead assays in a Hermes Wiscan system. (D and E) CTG-1677 and CTG-1703 PDX primary ovarian tumor cells were treated with vehicle or [sorafenib (2 μM) + sildenafil (2 μM) + celecoxib (2 μM)], as indicated in the panel. Twenty four h after drug treatment, cells were processed and subjected to live/dead assays in a Hermes Wiscan system. (F) GBM5/6/12/14 primary glioblastoma cancer cells were treated with vehicle or [sorafenib (0.5, 2.0 μM) + sildenafil (2 μM) + celecoxib (5 μM)], as indicated in the panel. Twenty four h after drug treatment, cells were processed and subjected to live/dead assays in a Hermes Wiscan system.